$380,000 of CORMEDIX INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R. 6214/S. 2730, Kidney Care Access Protection Act, including provisions related to healthcare and Medicare H.R. 7352/S. 4815, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2026"
You can find more data on corporate lobbying on Quiver Quantitative.
CRMD Insider Trading Activity
CRMD insiders have traded $CRMD stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- JANET DILLIONE sold 10,000 shares for an estimated $68,800
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
CRMD Hedge Fund Activity
We have seen 81 institutional investors add shares of CRMD stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP removed 1,463,297 shares (-74.4%) from their portfolio in Q1 2026, for an estimated $9,935,786
- DEEP TRACK CAPITAL, LP added 1,000,000 shares (+19.0%) to their portfolio in Q1 2026, for an estimated $6,790,000
- UBS GROUP AG added 902,210 shares (+141.8%) to their portfolio in Q1 2026, for an estimated $6,126,005
- TREXQUANT INVESTMENT LP added 560,637 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,806,725
- OBERWEIS ASSET MANAGEMENT INC/ added 406,000 shares (+50.4%) to their portfolio in Q1 2026, for an estimated $2,756,740
- SCULPTOR CAPITAL LP added 335,900 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,280,761
- GOLDMAN SACHS GROUP INC removed 317,452 shares (-38.3%) from their portfolio in Q1 2026, for an estimated $2,155,499
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CRMD Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 02/11/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/23/2026
- Needham issued a "Buy" rating on 01/08/2026
To track analyst ratings and price targets for CRMD, check out Quiver Quantitative's $CRMD forecast page.
CRMD Price Targets
Multiple analysts have issued price targets for $CRMD recently. We have seen 6 analysts offer price targets for $CRMD in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Leonid Timashev from RBC Capital set a target price of $14.0 on 04/28/2026
- Jason N. Butler from Citizens set a target price of $19.0 on 04/28/2026
- Roanna Ruiz from Leerink Partners set a target price of $14.0 on 04/28/2026
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 04/27/2026
- Serge Belanger from Needham set a target price of $15.0 on 04/27/2026
- Brandon Folkes from HC Wainwright & Co. set a target price of $13.0 on 01/23/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
